Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation

This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4

Detalles Bibliográficos
Autores principales: Ishida, Yuriko, Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Ogura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835993/
https://www.ncbi.nlm.nih.gov/pubmed/36655228
http://dx.doi.org/10.1183/23120541.00337-2022
_version_ 1784868774844825600
author Ishida, Yuriko
Ikeda, Satoshi
Sekine, Akimasa
Baba, Tomohisa
Ogura, Takashi
author_facet Ishida, Yuriko
Ikeda, Satoshi
Sekine, Akimasa
Baba, Tomohisa
Ogura, Takashi
author_sort Ishida, Yuriko
collection PubMed
description This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4
format Online
Article
Text
id pubmed-9835993
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-98359932023-01-17 Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation Ishida, Yuriko Ikeda, Satoshi Sekine, Akimasa Baba, Tomohisa Ogura, Takashi ERJ Open Res Correspondence This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4 European Respiratory Society 2022-12-12 /pmc/articles/PMC9835993/ /pubmed/36655228 http://dx.doi.org/10.1183/23120541.00337-2022 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Correspondence
Ishida, Yuriko
Ikeda, Satoshi
Sekine, Akimasa
Baba, Tomohisa
Ogura, Takashi
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_full Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_fullStr Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_full_unstemmed Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_short Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_sort pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835993/
https://www.ncbi.nlm.nih.gov/pubmed/36655228
http://dx.doi.org/10.1183/23120541.00337-2022
work_keys_str_mv AT ishidayuriko pharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT ikedasatoshi pharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT sekineakimasa pharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT babatomohisa pharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT oguratakashi pharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation

Ejemplares similares